LaunchPoint by Mosaic: Early-Stage Startup Program
Full antibody discovery.
30% below our standard rate.
Built for early-stage biotech.
LaunchPoint by Mosaic gives qualified seed-stage and pre-Series A companies access to Mosaic’s complete antibody discovery capabilities at 30% below our standard program rate. One flat fee. Work begins immediately. No surprises.
30%
Below our standard program rate for qualified companies
1
Flat fee. No add-ons, no scope changes
46
Research license candidate antibody sequences
6-8
Months from antigen to candidate-ready data
A Complete, Investor-Ready Data Package
Every LaunchPoint program delivers the full set of data investors want to see and everything you need to support internal decision-making and advance your program.
Antibody Sequences
Sequences of up to 46 Research License candidate antibodies. Full license for up to 10.
Binding + Epitope Data
Affinity characterization and epitope binning confirming target engagement.
Developability Scores
Manufacturability and stability assessment built into the workflow, not bolted on after.
Functional Screening Results
Activity confirmed in relevant assays.
Why LaunchPoint Exists
Early-stage biotech is caught in an impossible loop. You need proof-of-concept data before investors commit but generating that data requires capital you don’t have yet. Ideas alone don’t close Series A rounds. And without a clear path to start discovery, promising programs stall before they ever get going.
LaunchPoint breaks that cycle. One flat fee, 30% below our standard rate, gets you fully into discovery with work beginning immediately.
Special consulting packages are available as well.
What LaunchPoint Includes
A structured, end-to-end antibody discovery workflow designed to take you from antigen to candidate-ready data within a defined timeline.
Antigen Generation & Discovery
In vitro or hybridoma-based approaches, depending on your program.
High-Throughput Screening & Hit Identification
Panel-based screening to identify the strongest candidates across your full set.
Affinity Characterization & Epitope Binning
Binding and epitope data delivered across up to 92 antibodies.
Developability Assessment
Manufacturability and stability profiling up to 80 antibodies.
Functional Assay Development & Candidate Screening
Activity confirmed in assays tied to your program’s biology.
Who LaunchPoint Is For
LaunchPoint is designed for companies in the window between seed and Series A where the science is ready but the capital isn’t yet.
Seed-Stage Biotech
You’ve validated the biology but you’re pre-IND, working toward your first program. LaunchPoint gets you started without waiting for your next close.
Incubator Residents
Active programs housed in incubator or shared lab environments that need CRO-quality discovery without CRO pricing.
Academic Spinouts
Founder-led teams translating research into drug candidates who need an expert partner from day one.
Pre-Series A Companies
In the window before a major raise and need fundable data. LaunchPoint delivers exactly the data package investors want to see.
Do You Qualify?
LaunchPoint is a selective program and not every company will be accepted. We evaluate each one carefully to make sure the program is the right fit for your science and your stage.
Target Complexity
LaunchPoint is best suited for programs targeting soluble factors or single-pass transmembrane proteins with established expression and purification precedence.
Program Disclosure
All applicants are required to sign an NDA and share relevant program details so our scientific team can properly evaluate fit.
To get started, fill out our project intake form with details about your program. A member of our team will be in touch to discuss your science and evaluate your fit.
Powered by Mosaic Biosciences
LaunchPoint isn’t a separate program, it’s Mosaic’s full discovery capabilities, structured and priced for early-stage companies that qualify.
Mosaic Biosciences is a full-service biologics discovery CRO based in Boulder, Colorado, integrating in vivo and in vitro antibody discovery, protein engineering, bespoke assay development, and early developability analytics under one roof, the same end-to-end model that serves biopharma and biotech partners across the industry.
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracey Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
Sr. Director Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Scientific Depth. Collaborative Mindset.
Our team has advanced hundreds of discovery programs for biotechnology and pharmaceutical partners. [NAME] isn’t a separate or stripped-down offering. It’s Mosaic’s full discovery capabilities, structured and priced for early-stage companies that qualify.
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.
Ready to Start Your Discovery Program?
Tell us about your program by clicking Get Started below to fill out a short form and our team will be in touch within 3–5 business days to discuss your program and whether LaunchPoint is the right fit. Participation is limited. Mosaic evaluates all applications based on scientific fit and program alignment.
Start a conversation with our scientific team about your discovery program today